VIA
DNA icon

Vident Investment Advisory’s Ginkgo Bioworks DNA Stock Holding History

Vident Investment Advisory’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-2,053
Closed -$153K – 285
2023
Q2 		$153K Sell
2,053
-1,108
-35% -$65.6K 0.01% 1096
2023
Q1 		$168K Buy
3,161
+1,904
+151% +$121K 0.01% 1124
2022
Q4 		$84.9K Buy
1,257
+543
+76% +$49.9K ﹤0.01% 1117
2022
Q3 		$15K Buy
+714
New +$85.1K ﹤0.01% 1113

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

Vident Investment Advisory's DNA Position: Q3 2023 in Review

Vident Investment Advisory sold out of Ginkgo Bioworks (DNA) in Q3 2023, closing a stake of 2,053 shares — an estimated $153K sold.

Vident Investment Advisory first reported a position in DNA in Q3 2022 and held it in 4 quarters. The position peaked at $168K in Q1 2023. 348 funds tracked by Wall St. Rank hold DNA as of Q3 2023.

  • Vident Investment Advisory reported no remaining Ginkgo Bioworks position as of Q3 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 2,053 Ginkgo Bioworks shares in Q3 2023, an estimated $153K.
  • Vident Investment Advisory first reported a position in Ginkgo Bioworks in Q3 2022 and held it in 4 quarters.
  • Vident Investment Advisory's Ginkgo Bioworks position peaked at $168K in Q1 2023.
  • 348 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.